Group of rare, uniformly fatal neurodegenerative diseases. In humans they occur in 3 forms: sporadic (85% to 90% of cases), genetic (10% to 15%), and acquired (<1%).
Prions or proteinaceous infectious particles are the misshaped proteins responsible for causing transmissible spongiform encephalopathies, or prion diseases.
Present as very rapidly progressive dementias. Symptoms may vary, but include behavioural/psychiatric changes, memory impairment, visual disturbances, myoclonus, ataxia, language and hearing problems, and movement dysfunction.
Misdiagnosis is common, as Creutzfeldt-Jakob disease (CJD) can present similarly to other neurological conditions. Pathology currently is the only definitive way to diagnose prion disease, although biopsy and even autopsy may yield false-negative results.
Pre-mortem diagnostic tools that may be helpful include MRI, EEG, and CSF findings, as well as blood tests to rule out other conditions. Brain MRI, particularly diffusion-weighted imaging, has very high sensitivity and specificity for CJD, as does the real-time quaking-induced conversion (RT-QuIC) test on CSF.
Currently, there is no cure for prion disease, and treatment consists of management of symptoms and palliative care. Survival for most sporadic prion patients is generally about 1 year or less, whereas survival of genetic prion disease varies greatly from a few months to several years depending on the mutation.
Prion diseases (or transmissible spongiform encephalopathies) are a group of uniformly fatal neurodegenerative diseases characterised by progressive dementia and motor dysfunction. These diseases occur in spontaneous, genetic, and acquired forms. Patients commonly present with behavioural or personality changes, myoclonus, visual disturbances, movement problems, and/or incoordination. Survival from first symptom is typically <1 year in sporadic and acquired cases.
Department of Medicine
Division of Neurology
Centre for Prions and Protein Folding Diseases
University of Alberta
VS declares that she has no competing interests.
Dr Valerie Sim would like to gratefully acknowledge Dr Michael D. Geschwind, Dr Amy Kuo, and Dr R. Ronald Finley, the previous contributors to this monograph. MDG participates in the speakers' bureau for Pfizer, Forest, and Novartis; is consultant for MedaCorp, Gerson-Lehman Group, and Clinical Advisors Incorporated; and is an author of a number of references cited in this monograph. RRF participates in the speakers' bureau for Pfizer, Forest, and Novartis. AK declares that she has no competing interests.
Infectious Disease Specialist
Alabama Infectious Diseases Center
AH declares that he has no competing interests.
Associate Professor of Medicine
University of Southern California
Keck School of Medicine
RAL declares that he has no competing interests.
Chief and Professor of Medicine
Division of Infectious Diseases and International Health
University of Virginia Health System
WAP declares that he has no competing interests.
Use of this content is subject to our disclaimer